Skip to main content
. Author manuscript; available in PMC: 2022 Apr 1.
Published in final edited form as: Cancer Cytopathol. 2020 Nov 2;129(4):291–303. doi: 10.1002/cncy.22382

Table 2:

Risk of malignancy for various morphologic categories.

Study Morphologic category
Warthin tumor PA Monomorphic basaloid Pleomorphic basaloid Monomorphic oncocytoid Oncoytoid Gran/Vac Pleomorphic oncocytoid
Fibrillary Hyaline Mixed/Other Cystic Mucinous Other
Griffith et al. 2015 0 (0/29) 4.1% (2/49) 15.4% (2/13) 42.9% (3/7) 60.0% (6/10) 100.0% (4/4) 0 (0/11) 80.0% (8/10) 21.1% (4/19) 84.6% (11/13) 100.0% (21/21)
Griffith et al. 2017 0 (0/16) 14.3% (3/21) 14.3% (2/14) 83.3% (5/6) 60.0% (6/10) 75.0% (3/4) 25% (1/4) 80.0% (24/30) 40.0% (2/5) 100.0% (17/17) 100.0% (17/17)
Current study 0 (0/12) 0 (0/58) 50% (3/6) 71.4% (5/7) 47.4% (9/19) 100.0% (1/1) 0 (0/1) 92.3% (12/13) 33.3% (5/15) 100.0% (10/10) 88.9% (8/9)
Total 0 (0/57) 3.9% (5/128) 21.2% (7/33) 65.0% (13/20) 53.8% (21/39) 88.9% (8/9) 6.3% (1/16) 83.0% (44/53) 28.2% (11/39) 95.0% (38/40) 97.8% (46/47)

PA=pleomorphic adenoma